HPV Infection Clinical Trial
— APOSYOfficial title:
Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases
Main objective: -To determine Human Papilloma Virus (HPV) prevalence in patients with immune-mediated inflammatory diseases (IMID) using vaginal self-sampling (VSS), one year after VSS was proposed Primary endpoint: - To determine the prevalence of HPV infection (yes/no) after VSS proposal Secondary objectives: - To describe the HPV typology and the rate of co-infection (with several high-risk HPV (HR-HPV)) in this population - To describe the factors associated with the presence of HPV infection - To determine the rate of HPV clearance after one year, during the second screening at 12 months- To determine the percentage of pre-cancerous cervical lesions and cervical cancer in the event of subsequent cervical smear - To determine the factors associated with persistence (or non-clearance ) of HPV infection - To determine the factors associated with the presence of pre-cancerous and cancerous cervical lesions - To determine the characteristics, tolerance and acceptability of VSS - To determine the rate of cervical cancer screening carried out following French Health Authorities guidelines -To determine the HPV vaccination coverage Secondary endpoints: 1/ HPV typology and presence of co-infection (Yes/No, type) or HPV multi-infection (more than 2 HPV, Yes/No) identified on samples at inclusion and at 1 year. 2/ Explanatory variables: demographic, clinical, biological factors and treatments (corticoids, immunosuppressive treatments); variable to be explained: presence of HPV infection during follow-up. 3/ Characteristics, acceptability, obstacles and tolerance of VPA reported by self-questionnaire (including procedure failures, bleeding and pain). 4/ Up-to-date cervical cancer screening rate in accordance with HAS recommendations at 12 months post-procedure. 5/ Proportion of cervical cytological abnormalities and cervical cancer authenticated on cervico-vaginal smear, if performed (histological confirmation if available) during follow-up. 6/ Explanatory variables: demographic, clinical, biological factors and treatments (corticoids, immunosuppressants; variable to be explained: presence of cervical precancerous lesions and cervical cancer, authenticated on cervico-vaginal smear, if performed (histological confirmation if available) during follow-up. 7/ HPV vaccination coverage rate (measured on initial self-questionnaire) 8/ Prevalence of HR-HPV(s) at second screening at one year, in the case of initial positivity (Persistence of HPV infection (Yes/No). 9/ Explanatory variables: demographic, clinical, biological factors and treatments (corticoids, immunosuppressive treatments); variable to be explained: persistence of cervical HPV infection at one year (in the case of initial positivity).
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | March 2027 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 30 Years to 65 Years |
Eligibility | Inclusion Criteria: Women aged 30 to 65 years old presenting with MSIA, MSIA includes Systemic lupus erythematosus Sjögren's syndrome Systemic scleroderma Mixed connective tissue disease Inflammatory myositis Systemic sarcoidosis Systemic vasculitis Behçet's disease Adult-onset Still's disease IgG4-related disease Autoimmune cytopenia (autoimmune hemolytic anemia, immune thrombocytopenic purpura, Evans syndrome) Susac syndrome Followed in the internal medicine department of Bichat Hospital, Paris At least 1 scheduled visit between December 2023 and December 2025 Not up to date with gynecological follow-up (i.e., cervical cancer screening more than one year old or undatable) Exclusion Criteria: Patient under legal protection, guardianship, or trusteeship History of colpohysterectomy Not affiliated with a social security scheme (general or CMU) Absence of informed and written consent |
Country | Name | City | State |
---|---|---|---|
France | Service de Médecine Interne - Hôpital Bichat Claude Bernard | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Presence of HPV infection during follow-up (yes/no) | at inclusion and at one year | ||
Other | description of demographic factor | at inclusion and at one year | ||
Other | description of clinical factor | at inclusion and at one year | ||
Other | description of biological factor | at inclusion and at one year | ||
Other | description of treatment (corticoids, immunosuppressive treatments) | at inclusion and at one year | ||
Other | description of characteristics of VPA reported by self-questionnaire (including procedure failures, bleeding and pain). | at inclusion and at one year | ||
Other | description of acceptability of VPA reported by self-questionnaire (including procedure failures, bleeding and pain). | at inclusion and at one year | ||
Other | description of tolerance of VPA reported by self-questionnaire (including procedure failures, bleeding and pain). | at inclusion and at one year | ||
Other | description obstacles of VPA reported by self-questionnaire (including procedure failures, bleeding and pain). | at inclusion and at one year | ||
Other | Up-to-date cervical cancer screening rate in accordance with HAS recommendations | at 12 months post-inclusion. | ||
Other | Proportion of cervical cytological abnormalities if performed (histological confirmation if available) | during 1 year of follow-up | ||
Other | proportion of cervical cancer authenticated on cervico-vaginal smear, if performed (histological confirmation if available) | during 1 year of follow-up | ||
Other | presence of cervical precancerous lesions and cervical cancer | authenticated on cervico-vaginal smear, if performed (histological confirmation if available) | during 1 year of follow-up | |
Other | HPV vaccination coverage rate | (measured on initial self-questionnaire) | at inclusion | |
Other | Persistence of HPV infection | Prevalence of HR-HPV(s) at second screening , in the case of initial positivity | at one year | |
Primary | prevalence of HPV infection (yes/no) after VSS proposal | at one year | ||
Secondary | the HPV typology of co-infection (with several high-risk HPV (HR-HPV)) in this population | at inclusion and at one year after inclusion | ||
Secondary | The rate of co-infection (with several high-risk HPV (HR-HPV)) in this population | at inclusion and at one year after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04098744 -
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
|
Phase 2 | |
Completed |
NCT04083196 -
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
|
Phase 1 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Withdrawn |
NCT04430907 -
HPV Vaccine in Postpartum Women
|
||
Recruiting |
NCT02593968 -
Yallaferon in Chinese Population
|
Phase 2 | |
Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
Completed |
NCT02263378 -
A New Supplement for the Immune Response to HPV Infection
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04590521 -
HPV Vaccine Immunity in High-risk Women
|
Phase 4 | |
Recruiting |
NCT05829629 -
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
|
Phase 1 | |
Recruiting |
NCT06052033 -
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
|
N/A | |
Recruiting |
NCT05051852 -
HPV Viral Load in Predicting the Prognosis of LSIL
|
||
Completed |
NCT04155294 -
Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
|
||
Completed |
NCT06177236 -
Clinic or Self-Sampling for Cervical Cancer Screening
|
N/A | |
Active, not recruiting |
NCT04794660 -
The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"
|
Phase 3 | |
Recruiting |
NCT05509413 -
DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections
|
N/A | |
Recruiting |
NCT06137950 -
Interferon Alpha Therapy for Cervical CINI and HPV Infection
|
Phase 1 | |
Recruiting |
NCT04171505 -
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
|
||
Active, not recruiting |
NCT05524025 -
The SPOT-HPV Study
|
||
Recruiting |
NCT04998318 -
1:1 Comparison of the Pocket Colposcope in Kenya
|
N/A |